BIOTINYLATION OF ERYTHROCYTES FOR CLINICAL RESEARCH
(Abstract release date: 05/19/16)
EHA Library. de Back D. 06/09/16; 133124; E1575
Ms. Djuna de Back
Contributions
Contributions
Abstract
Abstract: E1575
Type: Eposter Presentation
Background
Within Sanquin there are currently several clinical transfusion protocols in development or already realized, where the objective is to assess the efficacy and safety of erythrocyte transfusions in certain categories of patients (MDS patients, IC patients). This question arises from the fact that up to 25% of the donor erythrocytes are cleared within 24 hours after a transfusion, a phenomenon that is becoming more and more linked to side effects of transfusion in the receiver. The mechanisms that ensure that erythrocytes are cleared are to a large extent still unclear. Identification of the routes that lead to the clearance of erythrocytes are especially important for the transfusion practice.
Aims
The goal is therefore to develop a standardized labelled blood product (GMP) that can be used for clinical research and evaluation of new blood products.
Methods
The yield after transfusion is difficult to measure. Although autologous red blood cells (RBCs) have a different genetic make-up than the transfused products, it is difficult to distinguish donor from recipient RBCs. Previously, donor erythrocytes were labelled with Chromium-51, a radioactive label a procedure that is not allowed in the Netherlands. Another option is to discriminate on the basis of differences in minor blood group antigens. This, however, is laborious and not always possible. A third possibility is to label erythrocytes with biotin, also known as vitamin B8. The advantage of labelling with biotin is that different concentrations of biotin labelling can be used, allowing the detection of several RBC transfusions in 1 patient.
Results
Former studies have shown that labelling with biotin is safe, also upon multiple exposures.We found that labelling with biotin does not affect the life span or function of the RBCs, and remains stable over time, also when the erythrocyte concentrate (EC) needs to be irradiated to prevent Graft vs. Host disease. Furthermore, labeling with different densities of biotin gives reliable identification of different populations of donor RBCs. However, about 12,5% of healthy volunteers may develop antibodies against biotin, without clinical consequences, and resolve spontaneously within a year time. Lastly, biotin can be stored in different concentrations, in bags that are compatible with blood bags, without loss of quality, and with preservation of properties.
Conclusion
Having arrived at the end of the validation study, it shows that EC that are labeled with biotin, can be produced in a standardized manner under GMP conditions, and can be used for clinical research and evaluation of new blood products.
Session topic: E-poster
Keyword(s): Blood transfusion, Erythrocyte
Type: Eposter Presentation
Background
Within Sanquin there are currently several clinical transfusion protocols in development or already realized, where the objective is to assess the efficacy and safety of erythrocyte transfusions in certain categories of patients (MDS patients, IC patients). This question arises from the fact that up to 25% of the donor erythrocytes are cleared within 24 hours after a transfusion, a phenomenon that is becoming more and more linked to side effects of transfusion in the receiver. The mechanisms that ensure that erythrocytes are cleared are to a large extent still unclear. Identification of the routes that lead to the clearance of erythrocytes are especially important for the transfusion practice.
Aims
The goal is therefore to develop a standardized labelled blood product (GMP) that can be used for clinical research and evaluation of new blood products.
Methods
The yield after transfusion is difficult to measure. Although autologous red blood cells (RBCs) have a different genetic make-up than the transfused products, it is difficult to distinguish donor from recipient RBCs. Previously, donor erythrocytes were labelled with Chromium-51, a radioactive label a procedure that is not allowed in the Netherlands. Another option is to discriminate on the basis of differences in minor blood group antigens. This, however, is laborious and not always possible. A third possibility is to label erythrocytes with biotin, also known as vitamin B8. The advantage of labelling with biotin is that different concentrations of biotin labelling can be used, allowing the detection of several RBC transfusions in 1 patient.
Results
Former studies have shown that labelling with biotin is safe, also upon multiple exposures.We found that labelling with biotin does not affect the life span or function of the RBCs, and remains stable over time, also when the erythrocyte concentrate (EC) needs to be irradiated to prevent Graft vs. Host disease. Furthermore, labeling with different densities of biotin gives reliable identification of different populations of donor RBCs. However, about 12,5% of healthy volunteers may develop antibodies against biotin, without clinical consequences, and resolve spontaneously within a year time. Lastly, biotin can be stored in different concentrations, in bags that are compatible with blood bags, without loss of quality, and with preservation of properties.
Conclusion
Having arrived at the end of the validation study, it shows that EC that are labeled with biotin, can be produced in a standardized manner under GMP conditions, and can be used for clinical research and evaluation of new blood products.
Session topic: E-poster
Keyword(s): Blood transfusion, Erythrocyte
Abstract: E1575
Type: Eposter Presentation
Background
Within Sanquin there are currently several clinical transfusion protocols in development or already realized, where the objective is to assess the efficacy and safety of erythrocyte transfusions in certain categories of patients (MDS patients, IC patients). This question arises from the fact that up to 25% of the donor erythrocytes are cleared within 24 hours after a transfusion, a phenomenon that is becoming more and more linked to side effects of transfusion in the receiver. The mechanisms that ensure that erythrocytes are cleared are to a large extent still unclear. Identification of the routes that lead to the clearance of erythrocytes are especially important for the transfusion practice.
Aims
The goal is therefore to develop a standardized labelled blood product (GMP) that can be used for clinical research and evaluation of new blood products.
Methods
The yield after transfusion is difficult to measure. Although autologous red blood cells (RBCs) have a different genetic make-up than the transfused products, it is difficult to distinguish donor from recipient RBCs. Previously, donor erythrocytes were labelled with Chromium-51, a radioactive label a procedure that is not allowed in the Netherlands. Another option is to discriminate on the basis of differences in minor blood group antigens. This, however, is laborious and not always possible. A third possibility is to label erythrocytes with biotin, also known as vitamin B8. The advantage of labelling with biotin is that different concentrations of biotin labelling can be used, allowing the detection of several RBC transfusions in 1 patient.
Results
Former studies have shown that labelling with biotin is safe, also upon multiple exposures.We found that labelling with biotin does not affect the life span or function of the RBCs, and remains stable over time, also when the erythrocyte concentrate (EC) needs to be irradiated to prevent Graft vs. Host disease. Furthermore, labeling with different densities of biotin gives reliable identification of different populations of donor RBCs. However, about 12,5% of healthy volunteers may develop antibodies against biotin, without clinical consequences, and resolve spontaneously within a year time. Lastly, biotin can be stored in different concentrations, in bags that are compatible with blood bags, without loss of quality, and with preservation of properties.
Conclusion
Having arrived at the end of the validation study, it shows that EC that are labeled with biotin, can be produced in a standardized manner under GMP conditions, and can be used for clinical research and evaluation of new blood products.
Session topic: E-poster
Keyword(s): Blood transfusion, Erythrocyte
Type: Eposter Presentation
Background
Within Sanquin there are currently several clinical transfusion protocols in development or already realized, where the objective is to assess the efficacy and safety of erythrocyte transfusions in certain categories of patients (MDS patients, IC patients). This question arises from the fact that up to 25% of the donor erythrocytes are cleared within 24 hours after a transfusion, a phenomenon that is becoming more and more linked to side effects of transfusion in the receiver. The mechanisms that ensure that erythrocytes are cleared are to a large extent still unclear. Identification of the routes that lead to the clearance of erythrocytes are especially important for the transfusion practice.
Aims
The goal is therefore to develop a standardized labelled blood product (GMP) that can be used for clinical research and evaluation of new blood products.
Methods
The yield after transfusion is difficult to measure. Although autologous red blood cells (RBCs) have a different genetic make-up than the transfused products, it is difficult to distinguish donor from recipient RBCs. Previously, donor erythrocytes were labelled with Chromium-51, a radioactive label a procedure that is not allowed in the Netherlands. Another option is to discriminate on the basis of differences in minor blood group antigens. This, however, is laborious and not always possible. A third possibility is to label erythrocytes with biotin, also known as vitamin B8. The advantage of labelling with biotin is that different concentrations of biotin labelling can be used, allowing the detection of several RBC transfusions in 1 patient.
Results
Former studies have shown that labelling with biotin is safe, also upon multiple exposures.We found that labelling with biotin does not affect the life span or function of the RBCs, and remains stable over time, also when the erythrocyte concentrate (EC) needs to be irradiated to prevent Graft vs. Host disease. Furthermore, labeling with different densities of biotin gives reliable identification of different populations of donor RBCs. However, about 12,5% of healthy volunteers may develop antibodies against biotin, without clinical consequences, and resolve spontaneously within a year time. Lastly, biotin can be stored in different concentrations, in bags that are compatible with blood bags, without loss of quality, and with preservation of properties.
Conclusion
Having arrived at the end of the validation study, it shows that EC that are labeled with biotin, can be produced in a standardized manner under GMP conditions, and can be used for clinical research and evaluation of new blood products.
Session topic: E-poster
Keyword(s): Blood transfusion, Erythrocyte
{{ help_message }}
{{filter}}